<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acyclovir: An overview</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acyclovir: An overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acyclovir: An overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kimon C Zachary, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 02, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">Acyclovir</a> is widely used in the treatment of herpesvirus infections, particularly herpes simplex virus (HSV) and varicella-zoster virus (VZV). An overview of the mechanisms of action of and resistance to acyclovir and its major clinical uses will be provided here.</p><p>Dosing and treatment of the specific clinical syndromes are described in greater detail on the appropriate topic reviews.</p><p>Use of <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> or <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a>, which are later generation agents with a similar mechanism of action, are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/8337.html" rel="external">"Valacyclovir: An overview"</a> and  <a class="medical medical_review" href="/d/html/8338.html" rel="external">"Famciclovir: An overview"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">Acyclovir</a> (9-[2-hydroxymethyl]guanine) is a nucleoside analog that selectively inhibits the replication of herpes simplex virus types 1 and 2 (HSV-1, HSV-2) and varicella-zoster virus (VZV). After intracellular uptake, it is converted to acyclovir monophosphate by virally-encoded thymidine kinase. This step does not occur to any significant degree in uninfected cells and thereby lends specificity to the drug's activity. The monophosphate derivative is subsequently converted to acyclovir triphosphate by cellular enzymes.</p><p><a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">Acyclovir</a> triphosphate competitively inhibits viral DNA polymerase by acting as an analog to deoxyguanosine triphosphate (dGTP). Incorporation of acyclovir triphosphate into DNA results in chain termination since the absence of a 3' hydroxyl group prevents the attachment of additional nucleosides. Acyclovir triphosphate has a much higher affinity for viral DNA polymerase than for the cellular homolog, yielding a high therapeutic ratio [<a href="#rid1">1,2</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Spectrum of activity</span><span class="headingEndMark"> — </span>In descending order of susceptibility, <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> is active against HSV types 1 and 2 (HSV-1, HSV-2), VZV, and Epstein-Barr virus (EBV) [<a href="#rid1">1</a>]. Cytomegalovirus (CMV), which does not encode thymidine kinase, is resistant at clinically achievable levels. Activity versus human herpes viruses 6 [<a href="#rid3">3</a>] and 8 [<a href="#rid4">4</a>] is similarly limited, and activity versus human herpes virus 7 is not well defined. </p><p class="headingAnchor" id="H4"><span class="h2">Mechanism of resistance</span><span class="headingEndMark"> — </span>Three mechanisms have been shown to endow herpes simplex viruses with resistance to <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>, a phenomenon rare in the immunocompetent host [<a href="#rid5">5,6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced or absent thymidine kinase</p><p class="bulletIndent1"><span class="glyph">●</span>Altered thymidine kinase activity resulting in decreased <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> phosphorylation</p><p class="bulletIndent1"><span class="glyph">●</span>Altered viral DNA polymerase with decreased affinity for <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> triphosphate</p><p></p><p><a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">Valacyclovir</a>, which is a prodrug of <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>, and <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a>, which is a prodrug of <a class="drug drug_general" data-topicid="9746" href="/d/drug information/9746.html" rel="external">penciclovir</a>, have a similar mechanism of action as acyclovir. Thus, HSV isolates resistant to acyclovir are also resistant to valacyclovir, famciclovir, and penciclovir. </p><p>Resistant herpes simplex viruses have been isolated from a variety of immunocompromised patients, including bone marrow and solid organ transplant recipients and those with the acquired immunodeficiency syndrome (AIDS) [<a href="#rid7">7</a>]. Analysis of isolates from a series of twelve AIDS patients with resistant HSV-2 indicated marked thymidine kinase deficiency in each case; these strains, not surprisingly, were cross-resistant to <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a>, which also requires phosphorylation for antiviral activity. However, <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a>, a pyrophosphate analogue, is also a potent inhibitor of HSV DNA polymerase and does not require phosphorylation for its antiviral activity; in clinical trials, foscarnet has demonstrated efficacy in patients with acyclovir-resistant infections [<a href="#rid8">8,9</a>]. (See  <a class="medical medical_review" href="/d/html/8288.html" rel="external">"Foscarnet: An overview"</a>.)</p><p>VZV resistance to <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> has been reported in patients with AIDS and other severely immunocompromising conditions. This rare problem usually occurs in the setting of chronic acyclovir therapy and has been linked to mutations in thymidine kinase, resulting in either deficient thymidine kinase or an enzyme with altered substrate specificity [<a href="#rid5">5,10</a>].</p><p class="headingAnchor" id="H5"><span class="h1">BASIC PHARMACOKINETICS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">Acyclovir</a> has modest oral bioavailability, about 15 to 30 percent, which decreases with higher doses. As an example, multiple oral doses of 200 to 800 mg yield steady-state peak plasma concentrations of 0.6 to 1.6 mcg/mL, whereas intravenous dosing at 5 to 10 mg/kg every eight hours results in concentrations of 10 to 20 mcg/mL. Thus, the intravenous formulation should be used for serious infections such as disseminated varicella in an immunocompromised host. (See  <a class="medical medical_review" href="/d/html/8336.html" rel="external">"Treatment of varicella (chickenpox) infection", section on 'Immunocompromised hosts'</a>.)</p><p><a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">Acyclovir</a> is not highly bound to plasma protein (about 15 percent) and achieves widespread tissue and fluid penetration, including the cerebrospinal fluid, in which acyclovir concentrations are approximately 50 percent of those in plasma. (See  <a class="medical medical_review" href="/d/html/8278.html" rel="external">"Herpes simplex virus type 1 encephalitis", section on 'Treatment'</a>.)</p><p>Excretion is predominantly renal, both by glomerular filtration and tubular secretion. The plasma half-life is two to three hours in patients with normal renal function; dosage modifications are required in the presence of renal insufficiency, which is a risk factor for acyclovir-related neurotoxicity [<a href="#rid11">11,12</a>]. </p><p>A buccal tablet formulation of <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>, which is placed on the upper gum (rather than swallowed), was approved by the United States Food and Drug Administration (FDA) in 2013 for treatment of recurrent herpes labialis in immunocompetent adults. A single 50 mg tablet yielded a mean salivary concentration of 440 mcg/mL 8 hours after application. However, the plasma concentration of acyclovir that was achieved after administration of the buccal formulation was insufficient to have antiviral activity at nonoral sites [<a href="#rid13">13</a>]. Thus, the buccal tablet should not be used for the treatment of herpes simplex virus (HSV) at nonoral sites.</p><p class="headingAnchor" id="H20908114"><span class="h1">DOSE ADJUSTMENTS</span></p><p class="headingAnchor" id="H20908121"><span class="h2">Reduced renal function</span><span class="headingEndMark"> — </span>Dose modification of <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> is recommended for patients with a reduced estimated glomerular filtration rate (eGFR) [<a href="#rid14">14-16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>If administered orally, the dose should be reduced for individuals with an eGFR ≤25 mL/minute/1.73 m<sup>2</sup></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If administered intravenously, the dose should be reduced for individuals with an eGFR ≤50 mL/minute/1.73 m<sup>2 </sup></p><p></p><p>Detailed dosing recommendations are available in the <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">Acyclovir</a> drug information monograph included within UpToDate.</p><p class="headingAnchor" id="H20908170"><span class="h2">Obesity</span><span class="headingEndMark"> — </span>In patients with obesity (eg, BMI ≥30), weight-based dosing should be scaled to ideal body weight (IBW) rather than actual body weight (ABW) to avoid an increased risk of toxicity [<a href="#rid15">15-19</a>]. <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">Acyclovir</a> is hydrophilic, not highly bound to plasma protein, and distributes mainly into body fluids and nonadipose tissue (see <a class="local">'Basic pharmacokinetics'</a> above). A calculator to determine IBW (using sex, height, and actual body weight) is available separately in UpToDate (<a class="calc calc_professional" href="/d/html/13489.html" rel="external">calculator 1</a>).</p><p class="headingAnchor" id="H6"><span class="h1">TOXICITY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">Acyclovir</a> is remarkably well tolerated in most patients [<a href="#rid20">20</a>]. There are, however, several important types of toxic reactions.</p><p class="headingAnchor" id="H7"><span class="h2">Acute renal failure</span><span class="headingEndMark"> — </span>Acute renal failure, produced by the precipitation of relatively insoluble <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> crystals in the renal tubules, is an occasional complication of intravenous therapy [<a href="#rid21">21,22</a>]. The risk can be minimized by prior hydration (with the urine output maintained above 75 mL/hour) and slow drug infusion over one to two hours [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/7229.html" rel="external">"Crystal-induced acute kidney injury"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Neurologic toxicity</span><span class="headingEndMark"> — </span>Rare reports of neurologic toxicity have included agitation, tremors, delirium, hallucinations, and myoclonus [<a href="#rid23">23-25</a>]; cases typically occur in patients with underlying renal failure. Severe neurotoxicity, characterized by delirium and coma, has been described at doses as low as 800 mg twice daily in patients requiring dialysis [<a href="#rid26">26</a>]. The potential for this complication is greater in patients treated with peritoneal dialysis, which is associated with minimal removal of <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H9"><span class="h1">USE IN PREGNANCY</span><span class="headingEndMark"> — </span>Although no controlled studies have been performed to establish the safety of <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> during pregnancy, several large observational studies have generated reassuring data:</p><p class="bulletIndent1"><span class="glyph">●</span>In an observational cohort of nearly 838,000 live-born infants in Denmark from 1996 to 2008, 1804 pregnancies had been exposed to <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>, <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a>, or <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a> during the first trimester of pregnancy [<a href="#rid28">28</a>]. However, exposure to antiviral therapy was not associated with an increased risk of a congenital anomaly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Analysis of 1129 pregnancies exposed to <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>, 712 during the first trimester, from 1984 to 1997, failed to reveal an increase in congenital anomalies when compared with the rate expected in the general population [<a href="#rid29">29</a>]. </p><p></p><p class="headingAnchor" id="H10"><span class="h1">USE OF ACYCLOVIR IN IMMUNOCOMPETENT PATIENTS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">Acyclovir</a> is used for the treatment of herpes simplex virus (HSV), herpes zoster, and primary varicella infection in immunocompetent and immunocompromised hosts. It is also occasionally used for post-exposure prophylaxis after exposure to varicella. Further information can be found in the appropriate topic selection.</p><p class="headingAnchor" id="H620875503"><span class="h1">IF THERE IS AN ACYCLOVIR SHORTAGE</span><span class="headingEndMark"> — </span>Shortages of intravenous (IV) <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> have occurred in the United States [<a href="#rid30">30,31</a>]. IV acyclovir is the drug of choice for: neonates with proven herpes simplex virus (HSV) disease, pregnant women with complicated HSV or varicella-zoster virus (VZV) infection, and individuals with herpes simplex encephalitis. During a shortage, IV acyclovir should be reserved for patients with these infections [<a href="#rid31">31</a>]. However, if IV acyclovir is not available, alternative agents must be used. Clinicians should check the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2FDrugs%2FDrugSafety%2FDrugShortages%2F&amp;token=SHauxSdf9qNc6lLK16E8IDV3KxAgJ9eAUWFzIj8OhB815GpcxXHQBvP95J5pU5yOpU7YfF%2F1DbhN%2Bx%2BGZZZZpQ%3D%3D&amp;TOPIC_ID=8332" target="_blank">United States Food and Drug Administration</a> (FDA) and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ashp.org%2Fdrug-shortages%2Fcurrent-shortages%2Fdrug-shortage-detail.aspx%3Fid%3D590&amp;token=j%2BtF41plvYHq0KcVLVNCgrwHIQR%2B7NiNor3Cv4%2BHvTd3WXYsCgkVtcpbpdBZ7HGOmKwBAqo0bjagZ9HnYdTuQUbp0LiSwMxfZVJFgm08mqo%3D&amp;TOPIC_ID=8332" target="_blank">American Society of Health-system pharmacists</a> websites for information about the availability of IV acyclovir.</p><p class="headingAnchor" id="H693179357"><span class="h2">Overview of alternative agents</span><span class="headingEndMark"> — </span>Guidance on the management and treatment of these various infections when a shortage occurs is listed below. Consultation with an infectious diseases specialist is recommended. All dosing recommendations for the antiviral agents listed below are for patients with normal renal function; dosage adjustments are required for patients with renal insufficiency.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">Ganciclovir</a> ─ Ganciclovir is an acyclic analog of the nucleoside guanosine that has established antiviral efficacy in the treatment of cytomegalovirus infections. Ganciclovir also inhibits the replication of other herpesviruses in vitro, including HSV-1 and HSV-2; however, there are few clinical data on the use of this antiviral medication for the clinical indications listed above.</p><p></p><p class="bulletIndent1">Clinicians need to be aware that <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> is associated with more toxicity than <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>, particularly bone marrow suppression (anemia, leukopenia and/or thrombocytopenia). Hematologic monitoring is recommended in patients receiving ganciclovir. Ganciclovir should be used in pregnancy only if the potential benefit outweighs the potential risk to the fetus. (See  <a class="medical medical_review" href="/d/html/8342.html" rel="external">"Ganciclovir and valganciclovir: An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">Foscarnet</a> ─ Foscarnet has been associated with decreased renal function and electrolyte abnormalities. Monitoring of renal function and electrolytes is essential in patients receiving foscarnet. In addition, patients should receive prehydration with normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> before each dose of foscarnet. The concomitant administration of other nephrotoxic agents should be avoided, when possible. (See  <a class="medical medical_review" href="/d/html/8288.html" rel="external">"Foscarnet: An overview", section on 'Toxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">Cidofovir</a> ─ Cidofovir does not cross the blood-brain barrier and should <strong>not</strong> be substituted for <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> in patients with central nervous system infections. </p><p></p><p class="headingAnchor" id="H273810246"><span class="h2">Management of clinical conditions when IV acyclovir is unavailable</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herpes simplex encephalitis</strong> — For suspected or documented HSV encephalitis we administer <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> (for infants ≤90 days old: 6 mg/kg IV every 12 hours; for infants &gt;90 days old, children, and adults: 5 mg/kg every 12 hours) [<a href="#rid31">31</a>]. If ganciclovir cannot be given, we suggest <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> (for infants and children: 60 mg/kg IV every 12 hours; for adults: 90 mg/kg IV every 12 hours or 60 mg/kg IV every 8 hours). (See  <a class="medical medical_review" href="/d/html/8278.html" rel="external">"Herpes simplex virus type 1 encephalitis", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal herpes simplex infection</strong> — For suspected neonatal HSV infection we suggest <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> (for infants ≤90 days old: 6 mg/kg IV every 12 hours; for infants &gt;90 days old: 5 mg/kg every 12 hours) [<a href="#rid31">31</a>]. If ganciclovir cannot be given, we suggest <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> (60 mg/kg IV every 12 hours). The duration of treatment is the same as it would be for <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>. </p><p></p><p class="bulletIndent1">Patients should be monitored closely for response to therapy because there is a lack of clinical experience with <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> for the treatment of neonatal HSV; this includes repeat sampling of cerebrospinal fluid for HSV polymerase chain reaction (PCR). (See  <a class="medical medical_review" href="/d/html/6040.html" rel="external">"Neonatal herpes simplex virus infection: Management and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Varicella pneumonia</strong> — For patients with suspected or documented varicella pneumonia we suggest <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> (for infants &lt;90 days old: 6 mg/kg IV every 12 hours; for infants &gt;90 days old, children, and adults: 5 mg/kg IV every 12 hours) [<a href="#rid31">31</a>]. If ganciclovir cannot be given, we suggest <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> (for infants and children: 60 mg/kg IV every 12 hours; for adults: 90 mg/kg IV every 12 hours or 60 mg/kg IV every 8 hours). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adults who have improved on IV <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> can be switched to a high dose of oral <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> (in adults: 2000 mg four times daily) provided that they are expected to absorb oral medications adequately. In adults who are not severely ill, it is reasonable to give a lower dose of valacyclovir (1000 mg three times daily). We do not recommend oral <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> in this situation since it is not highly bioavailable. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disseminated herpes simplex virus infection</strong> — HSV infection can cause disseminated disease in immunocompromised and immunocompetent hosts. For infants or for immunocompromised and/or severely ill children and adults, we suggest <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> (for infants &lt;90 days old: 6 mg/kg IV every 12 hours; for infants &gt;90 days old, children, and adults: 5 mg/kg IV every 12 hours) [<a href="#rid31">31</a>]. If ganciclovir cannot be given, we suggest <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> (for infants and children: 60 mg/kg IV every 12 hours; for adults: 90 mg/kg IV every 12 hours or 60 mg/kg IV every 8 hours). Adults who are improving on IV therapy can be switched to <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> (1000 mg orally three times daily). </p><p></p><p class="bulletIndent1">For immunocompetent children or adults who are not severely ill (eg, patients experiencing their initial HSV episode, who may have lesions distant from the site of inoculation), we suggest initial therapy with <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> (for children: 20 mg/kg per dose orally three times daily [maximum dose 1000 mg per dose]; for adults: 1000 mg orally three times daily).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disseminated herpes zoster infection</strong> — Varicella-zoster virus (VZV) infection can cause disseminated disease in immunocompromised and immunocompetent hosts. For immunocompromised patients or severely ill patients, we suggest <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> (for infants &lt;90 days old: 6 mg/kg IV every 12 hours; for infants &gt;90 days old, children, and adults: 5 mg/kg IV every 12 hours) [<a href="#rid31">31</a>]. If ganciclovir cannot be given, we suggest <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> (for infants and children: 60 mg/kg IV every 12 hours; for adults: 90 mg/kg IV every 12 hours or 60 mg/kg IV every 8 hours). Patients who are improving on IV therapy can be switched to <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> (for children: 20 mg/kg per dose orally three times daily [maximum dose 1000 mg per dose]; for adults: 1000 mg orally three times daily).</p><p></p><p class="bulletIndent1">For immunocompetent patients who are not severely ill, we suggest initial therapy with <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> (for children: 20 mg/kg per dose orally three times daily [maximum dose 1000 mg per dose]; for adults: 1000 mg orally three times daily). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Esophageal herpes simplex infection</strong> — For patients with HSV esophagitis who are unable to take medications orally due to odynophagia, we suggest <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> (5 mg/kg IV every 12 hours). If ganciclovir cannot be given, we suggest <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a> (40 mg/kg IV every 8 to 12 hours). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucocutaneous herpes simplex infections</strong> — Immunocompetent patients with mucocutaneous HSV infection can be treated with oral <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a>, or <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a>, or <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>. </p><p></p><p class="headingAnchor" id="H28068474"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">Acyclovir</a> is widely used in the treatment of herpesvirus infections, particularly herpes simplex virus (HSV) and varicella-zoster virus (VZV). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – After intracellular uptake, <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> is converted to acyclovir monophosphate by virally-encoded thymidine kinase; this step does not occur to any significant degree in uninfected cells and thereby lends specificity to the drug's activity. The monophosphate derivative is subsequently converted to acyclovir triphosphate, which leads to DNA chain termination. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of resistance</strong> – Acyclovir-resistant herpes simplex viruses are uncommon and are typically seen in immunocompromised patients, such as bone marrow and solid organ transplant recipients and those with the AIDS. Acyclovir-resistant herpes viruses are rarely detected in the immunocompetent host. (See <a class="local">'Mechanism of resistance'</a> above.)</p><p></p><p>Herpes simplex viral isolates that are resistant to <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> are also resistant to <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a>, <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a>, and <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a>. <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">Foscarnet</a> can be effective in this clinical scenario. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral versus intravenous therapy</strong> – The oral formulation of <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> has modest oral bioavailability and is suitable for most patients; however, the intravenous formulation should be used for serious infections (eg, herpes simplex encephalitis, disseminated varicella in an immunocompromised host). (See <a class="local">'Basic pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose adjustments</strong> – In patients with reduced kidney function, the dose of <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> may need to be reduced depending upon the formulation (intravenous [IV] versus orally [PO]) and the estimated glomerular filtration rate. Detailed dosing recommendations are available in the acyclovir drug information monograph included within UpToDate.</p><p></p><p class="bulletIndent1">In addition, for patients with a BMI ≥30, weight-based dosing of IV therapy should be scaled to ideal body weight (IBW) rather than actual body weight. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">Acyclovir</a> is generally well tolerated. Rare complications, seen almost exclusively with intravenous therapy, include acute renal failure and neurologic toxicity (eg, agitation, tremors, delirium, hallucinations, and myoclonus). (See <a class="local">'Toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use in pregnancy</strong> – Although no controlled studies among pregnant women have been performed, large observational studies have suggested that <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> use during the first trimester of pregnancy is not associated with an increased risk of teratogenicity. (See <a class="local">'Use in pregnancy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Whitley RJ, Gnann JW Jr. Acyclovir: a decade later. N Engl J Med 1992; 327:782.</a></li><li><a class="nounderline abstract_t">Hirsch MS, Swartz MN. Drug therapy: antiviral agents (second of two parts). N Engl J Med 1980; 302:949.</a></li><li><a class="nounderline abstract_t">Amjad M, Gillespie MA, Carlson RM, Karim MR. Flow cytometric evaluation of antiviral agents against human herpesvirus 6. Microbiol Immunol 2001; 45:233.</a></li><li><a class="nounderline abstract_t">Coen N, Duraffour S, Topalis D, et al. Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses. Antimicrob Agents Chemother 2014; 58:7312.</a></li><li><a class="nounderline abstract_t">Chatis PA, Crumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother 1992; 36:1589.</a></li><li><a class="nounderline abstract_t">Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004; 39 Suppl 5:S248.</a></li><li><a class="nounderline abstract_t">Englund JA, Zimmerman ME, Swierkosz EM, et al. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med 1990; 112:416.</a></li><li><a class="nounderline abstract_t">Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320:293.</a></li><li><a class="nounderline abstract_t">Hardy WD. Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. Am J Med 1992; 92:30S.</a></li><li><a class="nounderline abstract_t">Boivin G, Edelman CK, Pedneault L, et al. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 1994; 170:68.</a></li><li><a class="nounderline abstract_t">Laskin OL. Clinical pharmacokinetics of acyclovir. Clin Pharmacokinet 1983; 8:187.</a></li><li><a class="nounderline abstract_t">Adair JC, Gold M, Bond RE. Acyclovir neurotoxicity: clinical experience and review of the literature. South Med J 1994; 87:1227.</a></li><li class="breakAll">Sitavig (acyclovir) buccal tablets: highlights of prescribing information. Farmea, revised December 2019. https://sitavig.com/wp-content/uploads/2020/03/Sitavig-PI-Dec2019-FINAL.pdf (Accessed on May 05, 2020).</li><li><a class="nounderline abstract_t">Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29:562.</a></li><li class="breakAll">Acyclovir tablet and acyclovir capsule drug label information (revised September 2013); available at the US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d13b8cdd-59fd-472b-8125-a19f42ef5402 (Accessed on May 05, 2020).</li><li class="breakAll">Acyclovir sodium injection drug label information (revised April 2016); available at US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=badf347b-eeee-4239-9c74-966f262925aa (Accessed on May 04, 2020).</li><li><a class="nounderline abstract_t">Hernandez JO, Norstrom J, Wysock G. Acyclovir-induced renal failure in an obese patient. Am J Health Syst Pharm 2009; 66:1288.</a></li><li><a class="nounderline abstract_t">Polso AK, Lassiter JL, Nagel JL. Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review. J Clin Pharm Ther 2014; 39:584.</a></li><li><a class="nounderline abstract_t">Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis 1997; 25:112.</a></li><li><a class="nounderline abstract_t">Drugs for non-HIV viral infections. Treat Guidel Med Lett 2007; 5:59.</a></li><li><a class="nounderline abstract_t">Sawyer MH, Webb DE, Balow JE, Straus SE. Acyclovir-induced renal failure. Clinical course and histology. Am J Med 1988; 84:1067.</a></li><li><a class="nounderline abstract_t">Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003; 325:349.</a></li><li><a class="nounderline abstract_t">Feldman S, Rodman J, Gregory B. Excessive serum concentrations of acyclovir and neurotoxicity. J Infect Dis 1988; 157:385.</a></li><li><a class="nounderline abstract_t">Patel J, Hayes B, Bauler L, Mastenbrook J. Neurologic Acyclovir Toxicity in the Absence of Kidney Injury. J Emerg Med 2019; 57:e35.</a></li><li><a class="nounderline abstract_t">Gentry JL 3rd, Peterson C. Death Delusions and Myoclonus: Acyclovir Toxicity. Am J Med 2015; 128:692.</a></li><li><a class="nounderline abstract_t">Davenport A, Goel S, Mackenzie JC. Neurotoxicity of acyclovir in patients with end-stage renal failure treated with continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1992; 20:647.</a></li><li><a class="nounderline abstract_t">Stathoulopoulou F, Almond MK, Dhillon S, Raftery MJ. Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. Nephron 1996; 74:337.</a></li><li><a class="nounderline abstract_t">Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 2010; 304:859.</a></li><li class="breakAll">pregnancyregistry.gsk.com/acyclovir.html (Accessed on September 25, 2012).</li><li class="breakAll">US Food and Drug Administration. Current Drug Shortages. http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm (Accessed on December 04, 2012).</li><li class="breakAll">American Academy of Pediatrics. Red Book Online. Antiviral recommendations for herpes simplex virus (HSV) and varicella zoster virus (vzv) infections in hospitalized pediatric patients during the intravenous acyclovir shortage. http://aapredbook.aappublications.org/site/news/acyclovir.xhtml (Accessed on December 04, 2012).</li></ol></div><div id="topicVersionRevision">Topic 8332 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1288525" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Acyclovir: a decade later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6244492" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Drug therapy: antiviral agents (second of two parts).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11345533" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Flow cytometric evaluation of antiviral agents against human herpesvirus 6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25267682" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1416838" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Resistance of herpesviruses to antiviral drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494896" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2155570" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Herpes simplex virus resistant to acyclovir. A study in a tertiary care center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2536136" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1531285" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8014522" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6342900" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical pharmacokinetics of acyclovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7973922" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Acyclovir neurotoxicity: clinical experience and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7973922" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Acyclovir neurotoxicity: clinical experience and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19397464" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19397464" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19397464" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19574603" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Acyclovir-induced renal failure in an obese patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25203631" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9243045" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antimicrobial dosing in obese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17565338" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Drugs for non-HIV viral infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3376977" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Acyclovir-induced renal failure. Clinical course and histology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12811231" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3335815" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Excessive serum concentrations of acyclovir and neurotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31171414" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neurologic Acyclovir Toxicity in the Absence of Kidney Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25784625" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Death Delusions and Myoclonus: Acyclovir Toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1462997" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Neurotoxicity of acyclovir in patients with end-stage renal failure treated with continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8893152" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20736469" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
